Cancer Center Administration undertakes a range of activities essential to maximizing the effectiveness of CCSG-supported infrastructure and adding value to the UC Davis cancer research enterprise and the integrated cancer program with the Lawrence Livermore National Laboratory (LLNL). Administration oversight of CCSG expenditures ensures that they are used only in the ways specified by NCI Guidelines and the proposal for competitive renewal of NCI designation. Activities encompass support for scientific programs and collaborations, membership, shared resources, developmental funds used for pilot studies, recruitment and developing shared resources, clinical trial data management, and leadership organizations. The Administration adds value to the cancer research effort by planning and organizing """"""""Cross Talk"""""""" meetings, cancer biology seminars, an annual research symposium, and various collaborative conferences targeting Initiatives In breast cancer, Inflammation, stem cells, Imaging, brain tumors, and key research communities at UC Davis and LLNL. In addition, Administration is responsible for the coordination of Cancer Center membership, the Cancer Center Web site (http://cancer.ucdmc.ucdavis.edu), and various list serves and communication tools. Central operations, fiscal affairs, contract and grant administration, purchasing, event planning, proposal development, and public affairs are other core services provided by Cancer Center Administration to the Director, senior leaders and to the membership at large to advance strategic plans, new areas of research, and team science.

Public Health Relevance

Administration maintains the research organization and data about the research organization, provides staff expertise in financial management, grant proposal development scientific meeting development internal and external relations of significance to the research enterprise, and modern forms of electronic communication such as list servers and the Internet. In these ways. It builds the scope of cancer research at UCD.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-11
Application #
8741013
Study Section
Subcommittee G - Education (NCI)
Project Start
2002-07-01
Project End
2016-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
11
Fiscal Year
2013
Total Cost
$241,017
Indirect Cost
$84,020
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Braithwaite, Dejana; Miglioretti, Diana L; Zhu, Weiwei et al. (2018) Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort. JAMA Intern Med 178:494-501
Unger, Jakob; Sun, Tianchen; Chen, Yi-Ling et al. (2018) Method for accurate registration of tissue autofluorescence imaging data with corresponding histology: a means for enhanced tumor margin assessment. J Biomed Opt 23:1-11
Wang, Guobao; Corwin, Michael T; Olson, Kristin A et al. (2018) Dynamic PET of human liver inflammation: impact of kinetic modeling with optimization-derived dual-blood input function. Phys Med Biol 63:155004
Winer, Rachel L; Tiro, Jasmin A; Miglioretti, Diana L et al. (2018) Rationale and design of the HOME trial: A pragmatic randomized controlled trial of home-based human papillomavirus (HPV) self-sampling for increasing cervical cancer screening uptake and effectiveness in a U.S. healthcare system. Contemp Clin Trials 64:77-87
Withers, Sita S; Skorupski, Katherine A; York, Daniel et al. (2018) Association of macrophage and lymphocyte infiltration with outcome in canine osteosarcoma. Vet Comp Oncol :
Floc'h, Nicolas; Martin, Matthew J; Riess, Jonathan W et al. (2018) Antitumor Activity of Osimertinib, an Irreversible Mutant-Selective EGFR Tyrosine Kinase Inhibitor, in NSCLC Harboring EGFR Exon 20 Insertions. Mol Cancer Ther 17:885-896
Shih, Tsung-Chieh; Liu, Ruiwu; Wu, Chun-Te et al. (2018) Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. Clin Cancer Res 24:4319-4331
Weiss, Robert H (2018) Metabolomics and Metabolic Reprogramming in Kidney Cancer. Semin Nephrol 38:175-182
Hegde, John V; Shaverdian, Narek; Daly, Megan E et al. (2018) Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: Findings from a phase 2 trial. Cancer 124:521-529
Arun, Adith S; Tepper, Clifford G; Lam, Kit S (2018) Identification of integrin drug targets for 17 solid tumor types. Oncotarget 9:30146-30162

Showing the most recent 10 out of 836 publications